Online inquiry

IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10180MR)

This product GTTS-WQ10180MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets SELP gene. The antibody can be applied in Myocardial infarction research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_003005.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 6403
UniProt ID P16109
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SELP, LC1004-002(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ10180MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ8067MR IVTScrip™ mRNA-Anti-CD33, h2H12ec(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA h2H12ec
GTTS-WQ7925MR IVTScrip™ mRNA-Anti-CSF2, GSK3196165(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GSK3196165
GTTS-WQ12360MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ14715MR IVTScrip™ mRNA-Anti-SELP, SEG101(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SEG101
GTTS-WQ9361MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ5857MR IVTScrip™ mRNA-Anti-CD40, CHIR-12,12(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CHIR-12,12
GTTS-WQ9345MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ14900MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW